Bausch + Lomb launches its enVista Aspire monofocal and toric intraocular lenses in the European Union

News
Article

The launch follows a CE Mark received in late 2024

(Image Credit: AdobeStock/Oktay)

(Image Credit: AdobeStock/Oktay)

Bausch + Lomb announced the commercial launch of its enVista Aspire monofocal and toric intraocular lenses (IOLs) in the European Union after receiving a CE Mark late last year.

According to the company, the enVista Aspire IOLs combine novel Intermediate Optimised optics, designed for a broader depth of focus, with the proven benefits of the enVista platform to “address vision needs in today’s modern, digital world.” The lens also features 3C technology (Controlled Curvature Change) which are designed to harmonise the geometric power profile outward between the central base power and power at the periphery.1,2

The company also states that, unlike conventional spherical monofocal IOLs and low-order aspheric IOLs, enVista Aspire utilises higher-order aspheric coefficients on the posterior surface of the lens for a broader range of vision.1,2

Luc Bonnefoy, president of surgical at Bausch + Lomb commented on the release of the enVista Aspire IOLs in a press release from the company.1

“Surgeons around the world have long known the benefits of the enVista platform,” said Bonnefoy, “In the US, where enVista Aspire is currently available, surgeons and their patients appreciate the features of these monofocal lenses that are designed for a broader depth of focus, and we look forward to offering that feature in Europe as part of our comprehensive IOL portfolio.”

The company also notes that the Aspire IOLs can treat astigmatism and allows surgeons to “broaden the treatable astigmatism range in cataract surgery to as low as <1.0D at the corneal plane.” In the US, it was the first and only Low-Cyl toric (1.25D) below 1.5D at the IOL plane commercially available.1,2

References:

  1. Bausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union. Press Release. Published January 13, 2025. Accessed January 13, 2025. https://www.bausch.com/news/?id=244
  2. enVista Aspire. Bausch + Lomb. Accessed January 13, 2025. https://www.bauschsurgical.com/cataract/enVista-Aspire/

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
© 2025 MJH Life Sciences

All rights reserved.